Galien week of innovation
INCUBATOR/ACCELERATOR/EQUITY - Tuesday Oct. 25
2 PM - 3 PM ET
Incubators and accelerators are pivotal in developing innovative solutions to address humanity’s most pressing health challenges. Why are academic institutions, major medical centers, and significant life science companies launching incubators and accelerators to offer guidance to biotech, digital health, health information, and medical device start-ups? Beyond financial resources, how are these groups working to advance ideas into the marketplace, and what is their impact?
Chair Global Health and Purpose,
CEO, AION Labs
Managing Director, aMoon Velocity
Johannes Fruehauf, MD, PhD
Founder and President,
BioLabs and LabCentral
Design Technologies LLC
Dynamk Capital LLC
Global Head, Johnson & Johnson Innovation – JLABS,
Johnson & Johnson Innovation, LLC
Tom Daniel, MD
Board of Directors, Scripps Research;
Chair, LocanaBio, Inc.
Jérôme Van Biervliet
Managing Director, VIB Innovation & Business,
3 PM - 4 PM ET
An innovator’s connection to a leadership accelerator, incubator or private equity organization is a strong indicator of success. Financial support is part of the commitment, as are experience and connections. How do these investment and counseling groups help start-ups with their clinical trial design, navigate regulatory and payer system complexities or build a go-to marketing plan? Beyond access to cash, what makes the innovator’s connection to an accelerator, incubator or private equity group success critical?
Ron Cohen, MD
President, CEO and Founder
Acorda Therapeutics, Inc.
Chief Experience Officer,
CEO, Villgro Africa
Chief Clinical Trials Officer,